title: [Intoxication syndrome concomitant with recurrent streptococcal tonsillitis and its correction].
abstract: The objective of the present work was to study selected features of intoxication in the patients presenting with recurrent tonsillitis (RT) and managed by means of the combination of basal therapy with reamberine, a preparation showing the detoxication activity. A total of 70 patients with moderately severe recurrent streptococcal tonsillitis induced by infection with group A beta-hemolytic streptococci were available for the examination. Characteristics of endogenous intoxication were explored. The study has demonstrated that recurrent tonsillitis is associated with the development of the pronounced symptoms of endogenous intoxication (EI) as suggested by the enhanced leukocytic index of intoxication (LII) and the elevated levels of medium molecular weight molecules (MWM) with the simultaneous impairment of detoxication properties of albumin. Collectively, these changes are indicative of incompleteness of the pathological process that may be regarded as an unfavourable prognostic factor and suggests the risk of development of tonsillogenic pathology, its relapses, and chronization of the process. Taken together, these findings indicate the necessity of developing novel approaches to the treatment of recurrent tonsillitis with special reference to the use of pharmaceutical products possessed of detoxication activity. Reamberine introduced in the combined treatment of RT was shown to decrease the severity of intoxication as confirmed by normalization of LII and MWM levels as well as the improvement of detoxication properties of albumin. It is concluded that therapeutic efficacy of reamberine opens up wide prospects for its clinical applications.
authors.forename: V F
authors.initials: VF
authors.lastname: Pavelkina
authors.forename: M G
authors.initials: MG
authors.lastname: Laseeva
mesh_terms: D000328:Adult; D018450:Disease Progression; D004573:Electrolytes / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D019999:Pharmaceutical Solutions / Q000008:administration & dosage / Q000494:pharmacology; D012008:Recurrence; D012720:Severity of Illness Index; D013290:Streptococcal Infections / Q000150:complications / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000302:isolation & purification / Q000472:pathogenicity; D019802:Succinic Acid / Q000008:administration & dosage / Q000494:pharmacology; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D014069:Tonsillitis / Q000150:complications / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D004573:Electrolytes; D019999:Pharmaceutical Solutions; D019802:Succinic Acid